Recent Developments in the Molecular Mechanisms of Bone Metastasis and Potential Therapeutic Strategies: a Scoping Review



1 Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain

2 Department of Orthopedic Surgery, La Paz University Hospital, Madrid, Spain


The appearance of bone metastases (BM) in patients with advanced solid cancers (breast, prostate, lung) often worsens their quality of life and prognosis. Although none have been fully effective, several strategies have been used to combat BM. Hence, the need for new data that could be useful for treating bone metastasis. To this end, we reviewed the recent literature on the subject. About patients with prostate cancer, treatments with PIP5K1α inhibitors have been found to inhibit tumor invasion and metastasis, and G protein-coupled receptor class C group 5 member A (GPRC5A) could be a future therapeutic target. Regarding patients with breast cancer, we found the following: Asperolide A could be another curative drug; targeting transforming growth factor-beta (TGFβ) and bone morphogenetic protein (BMP) signaling pathways, along with osteoclast activity, could be a promising therapeutic strategy in the prevention of osteolytic bone destruction; TRAF6 inhibitors such as 6877002 appear promising; targeting the BMP4-SMAD7 signaling axis is a novel therapeutic strategy; there is favorable evidence for the potential therapeutic application of bone targeting immunostimulatory MOF (BT-isMOF) nanoparticles, and inhibition of IL4R and macrophages could have therapeutic benefits. For lung cancer, the role of LIGHT in osteolytic bone disease induced by metastatic non-small cell lung cancer should be highlighted.


Articles in Press, Accepted Manuscript
Available Online from 26 February 2022
  • Receive Date: 19 May 2021
  • Revise Date: 12 February 2022
  • Accept Date: 15 February 2022
  • First Publish Date: 26 February 2022